5,6-difluorobenzothiophene | 847684-98-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: 5,6-difluorobenzothiophene
• 英文别名: 5,6-difluorobenzo[b]thiophene；5,6-Difluoro-1-benzothiophene
• CAS: 847684-98-4
• 化学式: C₈H₄F₂S
• 分子量: 170.183
• InChiKey: ZZROMKZFGQSVSB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5,6-difluorobenzothiophene 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 溶剂黄146 为溶剂， 反应 4.0h， 以71%的产率得到3-Bromo-5,6-difluoro-benzo[b]thiophene
  参考文献：
  名称：

  以苯并硫脲（2,3- a）吡咯并（3,4- c）咔唑为糖苷配基的雷贝卡霉素类似物的高度收敛合成

  摘要：

  的利拜卡霉素类似物的高会聚的，可扩展的合成2在基于所述七个步骤和31％的总收率证实ñ -保护的构建块dibromomaleimide 7。描述了另外两个结构单元5,6-二氟-3-苯并噻吩硼酸6和5,6-二氟吲哚8的实际合成。

  DOI：

  10.1016/j.tetlet.2004.12.068
• 作为产物：
  描述：

  3,4-二氟苯硫酚 在 sodium ethanolate 作用下， 以 氯苯 为溶剂， 反应 39.0h， 生成 5,6-difluorobenzothiophene
  参考文献：
  名称：

  以苯并硫脲（2,3- a）吡咯并（3,4- c）咔唑为糖苷配基的雷贝卡霉素类似物的高度收敛合成

  摘要：

  的利拜卡霉素类似物的高会聚的，可扩展的合成2在基于所述七个步骤和31％的总收率证实ñ -保护的构建块dibromomaleimide 7。描述了另外两个结构单元5,6-二氟-3-苯并噻吩硼酸6和5,6-二氟吲哚8的实际合成。

  DOI：

  10.1016/j.tetlet.2004.12.068

文献信息

• [EN] GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTORS<br/>[FR] COMPOSÉS AMIDE DE QUINUCLIDINE À SUBSTITUANTS GÉMINAL, EN TANT QU'AGONISTES DES RÉCEPTEURS NICOTINIQUES DE L'ACÉTYLCHOLINE Α7
  申请人：FORUM PHARMACEUTICALS INC

  公开号：WO2016100184A1

  公开（公告）日：2016-06-23

  The present invention relates to novel geminal substituted quinuclidine amide compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of α7- nAChR, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering the compound or composition to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.

  本发明涉及新型的伏立康定酰胺化合物，以及相应的药物组合物，其适用于作为α7-nAChR的激动剂或部分激动剂，并且涉及制备这些化合物和组合物的方法，以及在维持、治疗和/或改善认知功能的方法中使用这些化合物和组合物，特别是将该化合物或组合物用于需要的患者的给药方法，例如患有认知缺陷和/或希望增强认知功能的患者，这些患者可能从中获益。
• Design and Synthesis of a Fluoroindolocarbazole Series as Selective Topoisomerase I Active Agents. Discovery of Water-Soluble 3,9-Difluoro-12,13-dihydro-13-[6-amino-β- <scp>d</scp>-glucopyranosyl]-5<i>H</i>,13<i>H</i>-benzo[<i>b</i>]- thienyl[2,3-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazole- 5,7(6<i>H</i>)-dione (BMS-251873) with Curative Antitumor Activity against Prostate Carcinoma Xenograft Tumor Model
  作者：Balu N. Balasubramanian、Denis R. St. Laurent、Mark G. Saulnier、Byron H. Long、Carol Bachand、Francis Beaulieu、Wendy Clarke、Milind Deshpande、Jeffrey Eummer、Craig R. Fairchild、David B. Frennesson、Robert Kramer、Frank Y. Lee、Mikael Mahler、Alain Martel、B. Narasimhulu Naidu、William C. Rose、John Russell、Edward Ruediger、Carola Solomon、Karen M. Stoffan、Henry Wong、Kurt Zimmermann、Dolatrai M. Vyas

  DOI：10.1021/jm034197s

  日期：2004.3.1

  A series of fluoroindolocarbazoles were studied with respect to their topoisomerase I activity, cytotoxicity, selectivity, and in vivo antitumor activity. Emerging from this series was BMS-251873, a potential clinical candidate possessing a robust pharmacological profile including curative antitumor activity against prostate carcinoma.

  研究了一系列氟吲哚并咔唑的拓扑异构酶I活性，细胞毒性，选择性和体内抗肿瘤活性。从该系列中诞生的是BMS-251873，这是一种潜在的临床候选药物，具有强大的药理特性，包括对前列腺癌的治愈性抗肿瘤活性。
• Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors
  申请人：AXOVANT SCIENCES GMBH

  公开号：US10183938B2

  公开（公告）日：2019-01-22

  The present invention relates to novel geminal substituted quinuclidine amide compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of α7-nAChR, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering the compound or composition to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.

  本发明涉及适用于作为α7-nAChR的激动剂或部分激动剂的新型宝石取代喹吖啶酰胺化合物及其药物组合物，以及制备这些化合物和组合物的方法，以及在维持、治疗和/或改善认知功能的方法中使用这些化合物和组合物的方法。特别是，将化合物或组合物施用给有需要的患者的方法，例如，有认知缺陷和/或希望提高认知功能的患者，这些患者可从中获益。
• GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTORS
  申请人：Axovant Sciences GmbH

  公开号：EP3233087A1

  公开（公告）日：2017-10-25
• GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTONIC ACETYLCHOLINE RECEPTORS
  申请人：AXOVANT SCIENCES GMBH

  公开号：US20170369486A1

  公开（公告）日：2017-12-28

  The present invention relates to novel geminal substituted quinuclidine amide compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of α7-nAChR, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering the compound or composition to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.